Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Study provides support for relationship between APOE4 gene and risk of Alzheimer's disease in Latinos

A brain-imaging study published today in the Archives of Neurology suggests that a major genetic risk factor for Alzheimer's disease in the Anglo population is also a risk factor for the disease in Latinos.

15 Apr 2010

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

An investigational intervention using naturally ocurring antibodies in human blood has preserved the thinking abilities of a group of mild- to moderate-stage Alzheimer's patients over 18 months and significantly reduced the rate of atrophy (shrinkage) of their brains, according to a study performed at the NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

15 Apr 2010

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company's adenosine 2a receptor antagonist (SYN-115) in Parkinson's disease. The data demonstrate that SYN-115 significantly improves measures of motor and non-motor function in patients with Parkinson's disease either alone or in combination with levodopa.

15 Apr 2010

USRC to acquire DCA

U.S. Renal Care, Inc., a privately-held leading provider of outpatient dialysis services, and Dialysis Corporation of America, a leading provider of outpatient kidney dialysis centers, announced today that they have entered into a definitive merger agreement for USRC to acquire DCA.

15 Apr 2010

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system therapeutics, today announced clinical results with its investigational new drug, Serdaxin®for the treatment of major depressive disorder.

15 Apr 2010

Interim data from Avid's florbetapir "Image-to-Autopsy" Phase III study to be presented

Avid Radiopharmaceuticals, Inc. today announced the presentation of interim data from its landmark florbetapir "Image-to-Autopsy" Phase III study. These data come from the first cohort of subjects in the trial and are the first ever Phase III results for an agent designed to image Alzheimer's disease pathology.

15 Apr 2010

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.

From Baxter International Inc. 15 Apr 2010

Researchers identify gene that appears to increase risk of Alzheimer's disease

Researchers have identified a gene that appears to increase a person's risk of developing late-onset Alzheimer's disease, the most common type of Alzheimer's disease. The research will be presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto, April 10 - 17, 2010.

15 Apr 2010

Epilepsy patients who take Ginkgo products face increased risk of seizures: Report

Restrictions should be placed on the use of Ginkgo biloba - a top-selling herbal remedy - because of growing scientific evidence that Ginkgo may increase the risk of seizures in people with epilepsy and could reduce the effectiveness of anti-seizure drugs, a new report concludes. The article appears in ACS' monthly Journal of Natural Products.

15 Apr 2010

First patient enrolled in Endologix percutaneous EVAR pivotal clinical trial

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, announced today that the first patient has been enrolled in the Company's prospective, multicenter, randomized clinical trial for a bilateral percutaneous approach to endovascular abdominal aortic aneurysm repair.

15 Apr 2010

Foods that protect from Alzheimer’s

In a recent study researchers have revealed what we always knew - salads, fish, fruits and nuts are good for us. It says that these food combinations are related to a reduced risk of getting the dreaded brain and memory disease called Alzheimer’s disease. This study published in the online edition of the reputed journal Archives of Neurology also says that lesser the amount of high-fat dairy foods like butter etc. and red meats, the lesser is the risk of Alzheimer’s disease.

13 Apr 2010

Benefits of moderate alcohol drinking on stroke risk counteracted by cigarette smoking

New research finds any beneficial effect of drinking moderate amounts of alcohol on stroke may be counteracted by cigarette smoking, according to research that will be presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto, April 10 - 17, 2010.

13 Apr 2010

New driving guideline for people with Alzheimer's disease

The American Academy of Neurology has issued a new guideline to help determine when people with Alzheimer's disease or another type of dementia should stop driving. The guideline is published in the April 12, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology, and was presented at the American Academy of Neurology's Annual Meeting in Toronto.

13 Apr 2010

Touching story of young man fighting Alzheimer's disease

In her new unwavering memoir, Jim's Journey: The Story of a Young Man with Early On-set Alzheimer's (published by Trafford Publishing), debut author Gretchen L Dausey reveals the touching story of her husband's battle against Alzheimer's disease and her unwavering support despite the inevitable degeneration of his mind and body.

13 Apr 2010

Antidepressants and mood stabilizers may benefit stroke victims

A study in rodents shows the growth of new neurons, also known as neurogenesis, lessens the severity of stroke and dramatically improves function following a stroke. The research, undertaken at the Buck Institute for Age Research, suggests that drugs shown to promote neurogenesis in rodents could have benefits for human stroke victims and that those drugs-which include antidepressants and mood stabilizers such as lithium-may be suitable for study in human clinical trials.

13 Apr 2010

Researchers may be one step closer to slowing the progression of Alzheimer's disease

Researchers may be one step closer to slowing the onset and progression of Alzheimer's disease. An animal study supported by the National Institute of Environmental Health Sciences, part of the National Institutes of Health, shows that by targeting the blood-brain barrier, researchers are able to slow the accumulation of a protein associated with the progression of the illness.

13 Apr 2010

Uninsured migraine sufferers likely to get inadequate treatment: Neurology

People with no health insurance are less likely than the privately insured to receive proper treatment for their migraines, according to a study published in the April 13, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

13 Apr 2010

Increase in circulating stem cells can be achieved through Stem-Kine: Study

A study published in the peer reviewed Journal of Translational Medicine demonstrated administration of Stem-Kine, a commercially available nutritional supplement, significantly elevated levels of two types of stem cells in circulation.

13 Apr 2010

Semel Institute for Neuroscience and Human Behavior awarded $14.9M for establishing new IPCN

The Semel Institute for Neuroscience and Human Behavior at UCLA has been awarded $14.9 million in American Recovery and Reinvestment Act funds to establish a center dedicated to interdisciplinary research on the role of genetic and environmental factors in neuropsychiatric and behavioral disorders.

13 Apr 2010

Lean mass may decline among Alzheimer's patients

Lean mass—the weight of an individual's bones, muscles and organs without body fat—appears to decline among patients with Alzheimer's disease, according to a report in the April issue of Archives of Neurology, one of the JAMA/Archives journals.

13 Apr 2010

Alzheimer's Disease News and Research

Further Reading

Study provides support for relationship between APOE4 gene and risk of Alzheimer's disease in Latinos

Investigational treatment with IGIV reduces brain atrophy in Alzheimer's patients

Synosia Therapeutics presents data from phase 2a clinical study of SYN-115 in PD

USRC to acquire DCA

Phase IIa clinical trial results of Serdaxin for treatment of MDD

Interim data from Avid's florbetapir "Image-to-Autopsy" Phase III study to be presented

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Researchers identify gene that appears to increase risk of Alzheimer's disease

Epilepsy patients who take Ginkgo products face increased risk of seizures: Report

First patient enrolled in Endologix percutaneous EVAR pivotal clinical trial

Foods that protect from Alzheimer’s

Benefits of moderate alcohol drinking on stroke risk counteracted by cigarette smoking

New driving guideline for people with Alzheimer's disease

Touching story of young man fighting Alzheimer's disease

Antidepressants and mood stabilizers may benefit stroke victims

Researchers may be one step closer to slowing the progression of Alzheimer's disease

Uninsured migraine sufferers likely to get inadequate treatment: Neurology

Increase in circulating stem cells can be achieved through Stem-Kine: Study

Semel Institute for Neuroscience and Human Behavior awarded $14.9M for establishing new IPCN

Lean mass may decline among Alzheimer's patients

Aneuro: A Year of Neuroscience in Review eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News